The ECOG tissue banks are a critical part of ECOG's translational science program, providing a valuable resource to investigators at both ECOG member and non-member institutions. This application proposes continued support for the coordination and operation of these banks with the goal of collecting, processing, and storing high-quality specimens and making them available to investigators for use in approved correlative science projects. ECOG will increase the marketing of its high quality banked specimens for use in cutting edge research which in turn will change clinical care. ECOG is an active participant in the NCI-Clinical Trials Cooperative Groups'Group Banking Committee (GBC) and is committed to working with the GBC, through ECOG representation on the Steering Committee and subcommittees, toward the common goal of a harmonized system for the collection, processing, storage, and distribution of specimens across all Cooperative Group Banks. The use of common techniques ensures that samples are of sufficient quality for use in cutting edge research, facilitates pooling specimens from multiple banks for large scale translational projects, and enhances the ability to compare results across projects. Common vocabularies and data structures, as well as common policies for specimen requests, make the system easier to navigate for ail investigators regardless of cooperative group membership status. This creates a collegial, robust and productive cancer research system. The three main ECOG specimen banks are the Solid Tumor Bank (the ECOG PCO-RL), the Leukemia Tissue Bank, and the Myeloma Tissue Bank. Each collects and banks well annotated specimens from Cooperative Group clinical trials according to strict SOPs based on recommended Best Practices and follows GBC practices to make them available to investigators.
Banked biospecimens from large cooperative group trials, with clinical annotation and linked follow-up data, can be used for many research projects. The most important projects are those which identify or validate biomarkers;genes or proteins which can be used to predict responses to treatment. The well annotated specimens in the ECOG banks can thus be used to further the mission of individualized therapy.
|Vu, Ly P; Prieto, Camila; Amin, Elianna M et al. (2017) Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. Nat Genet 49:866-875|
|Gu, Zhaohui; Churchman, Michelle; Roberts, Kathryn et al. (2016) Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nat Commun 7:13331|
|Iacobucci, Ilaria; Li, Yongjin; Roberts, Kathryn G et al. (2016) Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. Cancer Cell 29:186-200|
|Churchman, Michelle L; Low, Jonathan; Qu, Chunxu et al. (2015) Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia. Cancer Cell 28:343-56|
|DiPaola, Robert S; Chen, Yu-Hui; Bubley, Glenn J et al. (2015) A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802. Eur Urol 68:365-71|
|Perez-Andreu, Virginia; Roberts, Kathryn G; Xu, Heng et al. (2015) A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood 125:680-6|
|Willis, Scooter; De, Pradip; Dey, Nandini et al. (2015) Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs. Meta Gene 4:129-41|
|Park, Sun-Mi; Gönen, Mithat; Vu, Ly et al. (2015) Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program. J Clin Invest 125:1286-98|
|Villaruz, Liza C; Huang, Grace; Romkes, Marjorie et al. (2015) MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603. Clin Epigenetics 7:58|
|Cesano, Alessandra; Willman, Cheryl L; Kopecky, Kenneth J et al. (2015) Cell signaling-based classifier predicts response to induction therapy in elderly patients with acute myeloid leukemia. PLoS One 10:e0118485|
Showing the most recent 10 out of 165 publications